RecallRadar

FDA Drug recall D-1876-2019

Nucala (mepolizumab) Injection, 100 mg/mL Prefilled Syringe, Single-Dose, For subcutaneous use only, Rx Only, Manufactured by GlaxoSmithKli…

On 2019-10-02 the FDA classified a Class II recall of Nucala (mepolizumab) Injection, 100 mg/mL Prefilled Syringe, Single-Dose, For subcutaneous use only, Rx Only, Manufactured by GlaxoSmithKli… by Cardinal Health, citing temperature Abuse; Product stored and shipped outside of labeled storage requirements.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1876-2019
ClassificationClass II
Statusterminated
Initiated2019-09-06
Published2019-10-02
Last updated2026-09-13 11:52 UTC
CompanyCardinal Health
DistributionUS

Product

Nucala (mepolizumab) Injection, 100 mg/mL Prefilled Syringe, Single-Dose, For subcutaneous use only, Rx Only, Manufactured by GlaxoSmithKline LLC, Philadelphia, PA 19112, Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0892-42.

Reason

Temperature Abuse; Product stored and shipped outside of labeled storage requirements.

Identifiers

ndc0173-0881-01
ndc0173-0881-61
ndc0173-0892-01
ndc0173-0892-42
ndc0173-0892-61
ndc0173-0892-63
ndc0173-0904-42
code_infoLot #: S25X, Exp. 03/31/21

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1876-2019%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.